Status:
COMPLETED
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Relapsed or Refractory Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in p...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Confirmed diagnosis of RRMM
- Received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor
- Planning to receive elotuzumab in combination with pomalidomide and dexamethasone at physician's medical judgement OR
- Age ≥ 18 years
- Confirmed diagnosis of RRMM
- Received one to three prior therapies
- Planning to receive elotuzumab in combination with lenalidomide and dexamethasone at physician's medical judgement
Exclusion
- Participants with therapeutic indications for which elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone has not been approved in Taiwan
- Participants who are contraindicated for treated with elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone (as described in the Taiwan label)
- Participants who participate in other interventional clinical trials
Key Trial Info
Start Date :
December 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 17 2025
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06163040
Start Date
December 22 2023
End Date
March 17 2025
Last Update
July 31 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital- Chiayi
Chiayi City, Chiayi, Taiwan, 613
2
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, 80756
3
National Taiwan University Hospital
Taipei, Taiwan, 100229
4
China Medical University Hospital
Taoyuan, Taiwan, 40447